Rates Up, Guidance Absent: FSMA Re-inspection User Fees On Hold
This article was originally published in The Tan Sheet
Executive Summary
Without a guidance for requesting fee reductions, FDA will not bill firms for re-inspections of facilities found non-compliant with manufacturing regulations or for costs linked to a firm failing to comply with a recall order.